Moreover, a recent meta-analysis has highlighted the time-varying effects of SGLT2 inhibitors, showing that, while the relative reduction in hospitalization for heart failure was significant early on, the benefit tended to decrease over time [25]. The gene discussed is SLC5A2; the disease is heart failure.